10-Q: Bullfrog AI Holdings Reports First Quarter 2024 Results, Bolstered by Secondary Offering

Bullfrog AI Holdings reports a net loss of $1.92 million for the first quarter of 2024, despite a $5.7 million boost from a secondary public offering.

Summary

• Bullfrog AI Holdings reported a net loss of $1.92 million for the first quarter of 2024, compared to a net loss of $1.33 million for the same period in 2023.
• The company's operating expenses increased to $1.97 million, up from $1.19 million in the first quarter of 2023, driven by higher research and development and general and administrative costs.
• Bullfrog AI did not generate any revenue in the first quarter of 2024, consistent with the first quarter of 2023.
• The company completed a secondary public offering in the first quarter of 2024, raising approximately $5.7 million in net proceeds.
• As of March 31, 2024, Bullfrog AI had a cash balance of approximately $7.0 million.
• The company believes its current capital resources are sufficient to fund operations for approximately 12 months from the date of the filing, assuming no significant revenue is generated in 2024.
• The weighted average number of shares outstanding was 7,388,508 for the first quarter of 2024, compared to 4,840,023 for the same period in 2023.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to the increased net loss and lack of revenue, despite the successful capital raise. The company is still in an early stage and faces significant risks.

Positives

• The company successfully completed a secondary public offering, raising approximately $5.7 million in net proceeds.
• The company's cash balance increased significantly to approximately $7.0 million as of March 31, 2024.
• The company believes its current capital resources are sufficient to fund planned operations for approximately 12 months.

Negatives

• The company reported a net loss of $1.92 million for the first quarter of 2024, which is an increase from the $1.33 million loss in the same period of 2023.
• The company did not generate any revenue in the first quarter of 2024.
• Operating expenses increased significantly to $1.97 million in the first quarter of 2024, compared to $1.19 million in the same period of 2023.

Risks

• The company has a history of negative cash flows from operations and net losses since inception.
• The company's ability to continue as a going concern is dependent on its ability to generate revenue or secure additional funding.
• The company's future success depends on its ability to successfully develop and commercialize its AI/ML platform and drug assets.
• The company faces risks related to market acceptance of its products and services, competition, and regulatory changes.
• The company's research and development efforts are subject to risks of failure and delays.

Future Outlook

The company believes its current capital resources are sufficient to fund planned operations for approximately 12 months from the date of this filing, assuming no significant revenue is generated in 2024. The company intends to continue to evolve and improve its AI/ML platform, pursue strategic partnerships, and advance its drug development programs.

Management Comments

• Management believes the bfLEAP platform is ideally suited for evaluating pre-clinical and clinical trial data.
• Management aims to improve the odds of success in each stage of developing medicine.
• Management intends to utilize bfLEAP to enable the success of ongoing clinical trials or rescue late-stage failed drugs.
• Management believes the company's capital resources are sufficient to fund planned operations for approximately 12 months.

Industry Context

The company operates in the competitive and rapidly evolving fields of artificial intelligence, machine learning, and biopharmaceuticals. The company's focus on using AI/ML to improve drug development aligns with industry trends towards leveraging technology to reduce costs and increase efficiency. The company's strategy of acquiring and rescuing failed drug assets is also a common approach in the biopharmaceutical industry.

Comparison to Industry Standards

• Bullfrog AI's lack of revenue in the first quarter is not uncommon for early-stage biotech companies focused on R&D, similar to companies like Xometry or Ginkgo Bioworks which also focus on technology development and have yet to achieve significant revenue.
• The increase in operating expenses is typical for companies scaling up operations and investing in research and development, similar to companies like Amyris or Zymergen during their growth phases.
• The company's reliance on capital raises is also common in the biotech industry, where companies often need to secure funding to support their research and development efforts, similar to companies like CRISPR Therapeutics or Editas Medicine.
• The company's focus on AI/ML in drug discovery is aligned with the industry trend of using technology to improve drug development, similar to companies like Recursion Pharmaceuticals or Insitro.

Corporate Governance

Stakeholder Impact

• Shareholders may be concerned about the increased net loss and lack of revenue.
• Employees may be impacted by the company's financial performance and future plans.
• Customers and partners may be interested in the company's progress in developing its AI/ML platform and drug assets.
• Creditors may be concerned about the company's ability to repay its debts.

Next Steps

• The company intends to continue to evolve and improve its AI/ML platform.
• The company plans to leverage its proprietary AI/ML platform for drug development.
• The company will continue to pursue strategic partnerships and collaborations.
• The company will continue to advance its internal clinical development programs.
• The company will seek to secure the rights to other proprietary data sets.
• The company intends to gain access to later-stage clinical assets through partnerships or acquisitions.

Key Dates

Keywords

AI, Machine Learning, Drug Development, Biopharmaceutical, Clinical Trials, bfLEAP, Secondary Offering, Financial Results, Therapeutics, Data Analysis